LAWRENCE MORA: Open Payments
NPI 1205851615 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$970 in 44 payments from 13 companies in 2025. Trend: 2023 $1,069 · 2024 $1,032 · 2025 $970
Food & beverage: $970
| Company | Payments | Amount |
|---|---|---|
| Indivior Inc. | 8 | $213 |
| AstraZeneca Pharmaceuticals LP | 8 | $201 |
| GlaxoSmithKline, LLC. | 8 | $146 |
| Amgen Inc. | 4 | $86 |
| Almatica Pharma LLC | 4 | $77 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| ABBVIE INC. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Novo Nordisk Inc | 2 | $35 |
| Alkermes, Inc. | 1 | $28 |
Products named: SUBLOCADE, BREZTRI, TRELEGY ELLIPTA, LOREEV XR, OTEZLA, XIFAXAN, REXULTI, Rybelsus.
Industry payments across CA — which companies pay providers there.
